Allogene Therapeutics, Inc. Retained Earnings
Allogene Therapeutics, Inc. (ALLO) had Retained Earnings of -$2.10 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$2.10B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$2.05B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$2.01B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.97B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$2.10B 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$2.05B 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$2.01B 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$1.97B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$1.93B 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$1.88B 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$1.82B 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$1.76B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$1.69B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | -$1.63B 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$1.56B 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$1.48B 10-K · filed 2024-03-14 | -$1.47B 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$1.41B 10-K · filed 2024-03-14 | -$1.41B 10-Q · filed 2023-08-02 |
| 2023-03-31 | -$1.33B 10-K · filed 2024-03-14 | -$1.33B 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$1.23B 10-K/A · filed 2024-03-14 | -$1.24B 10-K · filed 2023-02-28 |
| 2022-09-30 | -$1.14B 10-K · filed 2024-03-14 | -$1.14B 10-Q · filed 2022-11-02 |
| 2022-06-30 | -$1.05B 10-K · filed 2024-03-14 | -$1.06B 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$973.16M 10-K · filed 2024-03-14 | -$983.20M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$894.55M 10-K/A · filed 2024-03-14 | -$903.35M 10-K · filed 2022-02-23 |
| 2021-09-30 | -$828.48M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$750.29M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | -$679.36M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | -$712.50M 10-K/A · filed 2024-03-14 | -$646.34M 10-K · filed 2021-02-25 |
| 2020-09-30 | -$577.77M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | -$511.58M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$450.60M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | -$396.12M 10-K · filed 2021-02-25 | |
| 2019-09-30 | -$335.09M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | -$284.36M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | -$243.11M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | -$211.53M 10-K · filed 2020-02-27 | |
| 2018-09-30 | -$181.02M 10-Q · filed 2018-11-21 | |
| 2017-12-31 | -$23.00K 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |